Skip to main content

Viral MIP-II Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB346

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
MAB346
MAB346-SP

Key Product Details

Species Reactivity

Validated:

Viral

Cited:

Human

Applications

Validated:

Western Blot

Cited:

ELISA Development

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 82206

Product Specifications

Immunogen

E. coli-derived recombinant human herpes virus-8 MIP-II
Leu24-Arg94
Accession # AAC57093

Specificity

Detects viral MIP-II in direct ELISAs and Western blots. In direct ELISAs, no cross‑reactivity with recombinant viral (rv) MIP-I, rvCMV UL146, recombinant human MIP-1 alpha or recombinant mouse MIP-1 alpha is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for Viral MIP-II Antibody

Application
Recommended Usage

Western Blot

1 µg/mL
Sample: Recombinant Viral MIP-II (Catalog # 601-VB) under non-reducing conditions only

Formulation, Preparation, and Storage

Purification

Protein A or G purified from ascites

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: MIP-II

Human herpesvirus-8 (HHV-8)/Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gamma herpesvirus with homology to herpesvirus Saimiri and Epstein-Barr virus. HHV‑8 is etiologically linked to Kaposi’s sarcoma and a B-cell lymphoma known as primary effusion lymphoma. HHV-8 has been shown to encode a variety of immunomodulatory proteins which were apparently pirated from cellular genes by the virus. Three chemokine-like proteins, vMIP-I, vMIP-II and vMIP-III have been found to be encoded within the HHV-8 genome. Viral MIP-II cDNA encodes a 94 amino acid (aa) precursor protein with a 23 aa signal peptide that is cleaved to yield a 71 aa mature protein. Among human chemokines, vMIP-II is most closely related to MIP-1 alpha, sharing approximately 41% amino acid sequence identity. At the amino acid sequence level, vMIP-I and vMIP-II also share 48% identity. vMIP-I and vMIP-II are more closely related to one another phylogenetically than to other human chemokines, suggesting that they may have arisen by gene duplication within the virus rather than by two independent gene aquisitions. vMIP-II binds to the CCR3 chemokine receptor through which Eotaxin and other beta chemokines activate eosinophils. vMIP-II has been shown to activate and chemoattract human eosinphils. Both vMIP-I and vMIP-II have been shown to partially block HIV infection of peripheral blood mononuclear cells. vMIP-I and vMIP-II have also been found to be highly angiogenic in the chorioallantoic assay, suggesting that they may be partially responsible for the marked vascularity seen in KSHV-associated tumors.

References

  1. Moore, P.S. et al. (1996) Science 274:5293.
  2. Boshoff, C. et al. (1997) Science 278:290.

Long Name

Macrophage Inflammatory Protein II

Alternate Names

MIPII

UniProt

Additional MIP-II Products

Product Documents for Viral MIP-II Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Viral MIP-II Antibody

For research use only

Loading...
Loading...
Loading...
Loading...